CTIS2023-506000-50-00进行中（未招募）1 期
A Phase 2a Randomised, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate to Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA - D8210C00003
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •18 to 80 years of age inclusive, at the time of signing the informed consent., Male and/or female: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. At the end of the Run-in period (Visit 3), participants must fulfil the following additional criteria in order to be randomised into the study and enter the Treatment period: 1. Pre-BD FEV1 between = 40% and = 90% predicted. 2. A pre-BD/pre-IMP dose FEV1 at Visit 3 that has not increased or decreased by 20% or more from the pre-BD FEV1 recorded at Visit 1 and at Visit 2. 3. An ACQ-6 score of = 1.5. 4. At least 80% compliance with usual asthma background medication during Run-in period (from Visit 2 to Visit 3) based on the daily asthma ePROs. 5. Minimum 80% compliance with daily eCOAs (electronic Clinical Outcome Assessments) during the Run-in period and during the 14 days preceding Visit 3. 6. For female participants, a negative urine pregnancy test prior to administration of IMP, Treated with medium-high dose ICS in combination with LABA at a stable dose for at least 3 months prior to Visit 1., Documented history of = 1 severe asthma exacerbation within 1 year prior to Visit 1., Morning pre-BD FEV1 between = 40% and = 90% predicted at Visit 1 and Visit 3., Able to perform acceptable lung function testing for FEV1 according to ATS/ERS 2019 acceptability criteria., Documented evidence of asthma in the 10 years up to or including Visit 1., An ACQ-6 score = 1.5 at Visit 1 and at Visit 3., Able and willing to comply with the requirements of the CSP including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at the study site, and use electronic devices, eg, ePRO device and spirometer, Body weight of = 40 kg and body mass index of < 35 kg/m2
排除标准
- •A severe asthma exacerbation within 8 weeks prior to randomisation, Current or prior history of alcohol or drug abuse (including marijuana), as judged by the investigator, History of malignancy other than superficial basal cell carcinoma, Treatment with systemic corticosteroid within 4 weeks (oral) or 8 weeks (intramuscular) before Visit 1, Any immunosuppressive therapy within 12 weeks prior to Visit 1, Treatment with marketed biologics within 6 months of Visit 1 or 5 half-lives, whichever is longer, Inhaled corticosteroid plus fast-acting ß2 agonist as a reliever is not allowed 15 days prior to Visit 1, during Screening/Run-in and throughout the Treatment period and preferably 1 week after the last dose of IMP, Live, attenuated, or mRNA vaccines within 4 weeks of Visit, Immunoglobulin or blood products within 4 weeks of Visit 1, Any immunotherapy within 6 months of Visit 1, except for stable maintenance dose allergen-specific immunotherapy started at least 4 weeks prior to Visit 1 and expected to continue through to the end of the Follow-up period, Participant treated with any investigational drug within 4 months or 5 half-lives, whichever is longer, prior to Visit 1, History of herpes zoster reactivation, Participants with a known hypersensitivity to AZD4604 or any of the excipients of the product, Abnormal findings identified on physical examination, ECG, or laboratory testing, For female participants only – currently pregnant (confirmed with positive pregnancy test) or breast-feeding, Current smokers or participants with smoking history = 10 pack-years, Participants with a known long-term exposure to occupational asbestos, silica, radon, heavy metals, and polycyclic aromatic hydrocarbons, Positive family history of lung cancer, Positive urine cotinine test or exhaled carbon monoxide test at Visit 1 and at any timepoint throughout the study, Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site), Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements, Donation of blood (= 450 mL) within 3 months or donation of plasma within 14 days before Visit 1, Participants with a significant COVID-19 illness within 6 months of enrollment, Clinically important pulmonary disease other than asthma, Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could: -affect the safety of the participant throughout the study, -influence the findings of the study or the interpretation, or -impede the participant’s ability to complete the entire duration of study, Any clinically significant cardiac or cerebrovascular disease, History of venous thromboembolism, Participants who, as judged by the investigator, have evidence of active TB, or latent TB without completion of an appropriate course of treatment or appropriate ongoing prophylactic treatment, Participants with a recent history of, or who have a positive test for, infective hepatitis or unexplained jaundice, or participants who have been treated for hepatitis B, hepatitis C, or HIV
研究者
相似试验
进行中（未招募）
1 期
This is a trial that is studying a new inhaled medicine, MDT-637, that is being researched for the treatment of a viral infection of the lungs that typically affects the young and the elderly (Respiratory Syncytial Virus, RSV). Adult volunteers will be infected with RSV (the infection is typically mild in adults), half of these volunteers will be treated with MDT-637, and the other half will receive placebo which has no effect on RSV.EUCTR2012-001107-20-GBMicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd.143
招募中
2 期
Study to Assess the Effectiveness and Safety of AZD4604 in Adult Patients with Uncontrolled Moderate-to-Severe Asthma – The AJAX StudyCTRI/2024/04/065120AstraZeneca AB
尚未招募
2 期
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell DiseaseHaematological DisordersPACTR202206488890527Bausch Health America60
已完成
2 期
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseSickle Cell Disease patients with history of VOCsAnemia, Hemolytic, Congenital, Hematologic Diseases,LBCTR2022095104Bausch Health LLC9
进行中（未招募）
1 期
A Phase 2a Study of Efinopegdutide in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated SteatohepatitisCTIS2024-510923-20-00Merck Sharp & Dohme LLC91